2023-05-08 13:41:50来源：美国临床肿瘤学会（ASCO2023）年会阅读：47次
一年一度的全球肿瘤界盛会-美国临床肿瘤学会（ASCO）年会将于当地时间6月2日-6月6日召开。ASCO年会是世界上规模最大、学术水平最高、最具权威的临床肿瘤学会议，致力于癌症的预防、治疗和改善患者管理，以展示肿瘤的基础研究和临床最新研究为特点，讨论当前国际先进的治疗方法。随着中国临床研究在肿瘤领域的快速成长，中国在世界肿瘤领域中也发挥着日益重要的作用。此次会议上，中国研究Poster Discussion Session共入选22项。期待中国专家在ASCO年会上展现风采！
乳腺癌-转移性
Breast Cancer—Metastatic
摘要号：1017
Poster Bd #: 238
标题：LEONARDA-1: Phase III randomized study of lerociclib plus fulvestrant in patients with HR+, HER2- locally advanced or metastatic breast cancer that has progressed on prior endocrine therapy.
报告人：徐兵河
单位：中国医学科学院肿瘤医院
摘要号：1021
Poster Bd #: 242
标题：HER2-low status discordance between primary and recurrent/metastatic breast cancer in a large-scale cohort.
报告人：林明曦
单位：复旦大学附属肿瘤医院
在研疗法-免疫治疗
Developmental Therapeutics—Immunotherapy
摘要号：2520
Poster Bd #: 362
标题：A phase 1/2a study of T3011, an oncolytic HSV expressing IL-12 and PD-1 antibody, administered via intratumoral (IT) injection as monotherapy in advanced solid tumors.
报告人：季冬梅
单位：复旦大学附属肿瘤医院
摘要号：2526
Poster Bd #: 368
标题：A phase 1/2 study of the TORC1/2 inhibitor onatasertib combined with toripalimab in patients with advanced solid tumors.
报告人：Pei Shu, PhD
单位：四川大学华西医院
在研疗法-分子靶向药物和肿瘤生物学
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
摘要号：3011
Poster Bd #: 209
标题：FUTURE-SUPER: A randomized, subtyping-based umbrella phase II trial for first-line treatment of metastatic triple-negative breast cancer.
报告人：邵志敏
单位：复旦大学附属肿瘤医院
摘要号：3016
Poster Bd #: 214
标题：First-in-human dose escalation and expansion study of SYSA1801, an antibody-drug conjugate targeting claudin 18.2 in patients with resistant/refractory solid tumors.
报告人：王雅坤
单位：北京大学肿瘤医院
摘要号：3017
Poster Bd #: 215
标题：ARTEMIS-001: Phase 1 study of HS-20093, a B7-H3–targeting antibody-drug conjugate, in patients with advanced solid tumor.
报告人：段建春
单位：中国医学科学院肿瘤医院
胃肠道肿瘤-结直肠癌和肛门癌
Gastrointestinal Cancer—Colorectal and Anal
摘要号：3516
Poster Bd #: 216
标题：Adjuvant systemic chemotherapy with or without hepatic arterial infusion of floxuridine in patients following colorectal cancer liver metastases resection (HARVEST): A prospective, randomized controlled trial.
报告人：李宇红
单位：中山大学肿瘤防治中心
胃肠道肿瘤-胃食管癌、胰腺癌和肝胆癌
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
摘要号：4015
Poster Bd #: 336
标题：A phase 2 randomized, open-label, multicentre study of sintilimab and anlotinib in combination with gemcitabine plus cisplatin (GemCis) as first-line therapy in patients (pts) with advanced biliary tract cancer (BTC): SAGC.
报告人：应杰儿
单位：浙江省肿瘤医院
摘要号：4023
Poster Bd #: 344
标题：Neoadjuvant hepatic arterial infusion chemotherapy with FOLFOX could improve outcomes of resectable BCLC stage A/B hepatocellular carcinoma patients beyond Milan criteria: A multi-center, phase 3, randomized, controlled clinical trial.
报告人：韦玮
单位：中山大学肿瘤防治中心
妇科肿瘤
Gynecologic Cancer
摘要号：5520
Poster Bd #: 214
标题：Neoadjuvant camrelizumab plus chemotherapy for locally advanced cervical cancer (NACI study): A prospective, single-arm, phase II trial.
报告人：孙朝阳
单位：华中科技大学同济医学院附属同济医院
头颈肿瘤
Head and Neck Cancer
摘要号：6009
Poster Bd #: 1
标题：Final overall survival analysis of JUPITER-02: A phase 3 study of toripalimab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (NPC).
报告人：麦海强
单位：中山大学肿瘤防治中心
血液恶性肿瘤-白血病，骨髓增生异常综合征和同种异体移植
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
摘要号：7015
Poster Bd #: 145
标题：A randomized, double-blind, phase 3 study of jaktinib versus hydroxyurea (HU) in patients (pts) with intermediate-2 or high-risk myelofibrosis (MF).
报告人：Yi Zhang
单位：浙江大学医学院第一附属医院
血液系统恶性肿瘤-浆细胞疾病
Hematologic Malignancies—Plasma Cell Dyscrasia
摘要号：8010
Poster Bd #: 2
标题：Long-term remission and survival in patients with relapsed or refractory multiple myeloma after treatment of LCAR-B38M CAR-T: At least 5-year follow-up in LEGEND-2.
报告人：糜坚青
单位：上海交通大学医学院附属瑞金医院
肺癌-非小细胞局部-区域性/小细胞/其他胸部肿瘤
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
摘要号：8518
Poster Bd #: 145
标题：Phase II study of durvalumab plus olaparib as maintenance therapy in extensive-stage small-cell lung cancer (TRIDENT): Preliminary efficacy and safety results.
报告人：黄岩
单位：中山大学肿瘤防治中心
肺癌-转移性非小细胞肺癌
Lung Cancer—Non-Small Cell Metastatic
摘要号：9014
Poster Bd #: 2
标题：Safety and preliminary efficacy of YK-029A, a novel EGFR TKI, in patients with advanced NSCLC harboring ex20ins, T790M or rare mutations.
报告人：段建春
单位：中国医学科学院肿瘤医院
摘要号：9015
Poster Bd #: 3
标题：FAK inhibition with novel FAK/ALK inhibitor APG-2449 could overcome resistance in NSCLC patients who are resistant to second-generation ALK inhibitors.
报告人：马宇翔
单位：中山大学肿瘤防治中心
摘要号：9025
Poster Bd #: 1
标题：SI-B001 plus chemotherapy in patients with locally advanced or metastatic EGFR/ALK wild-type non-small cell lung cancer: A phase II, multicenter, open-label study.
报告人：赵媛媛
单位：中山大学肿瘤防治中心
黑色素瘤/皮肤癌
Melanoma/Skin Cancers
摘要号：9510
Poster Bd #: 273
标题：Efficacy and safety of tunlametinib in patients with advanced NRAS-mutant melanoma: A multicenter, open-label, single-arm, phase 2 study.
报告人：斯璐
单位：北京大学肿瘤医院
摘要号：9514
Poster Bd #: 277
标题：NeoPlus: A phase II study of neoadjuvant lenvatinib and pembrolizumab in resectable mucosal melanoma.
报告人：毛丽丽
单位：北京大学肿瘤医院
儿科肿瘤学
Pediatric Oncology
摘要号：10023
Poster Bd #: 329
标题：A multicenter, open-label, single-arm phase 1/2 study to evaluate the safety and efficacy of FCN-159 in pediatric participants with neurofibromatosis type 1.
报告人：胡晓洁
单位：上海第九人民医院
预防、降低风险和遗传性癌症
Prevention, Risk Reduction, and Hereditary Cancer
摘要号：10513
Poster Bd #: 146
标题：Famitinib for familial adenomatous polyposis-associated aggressive desmoid tumors: A single-center exploratory study.
报告人：葛赛
单位：北京大学肿瘤医院
备注：排名不分先后，按照摘要号进行
如有遗漏或任何问题，请给我们留言~